✦ LIBER ✦

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions

✍ Scribed by Zoccolella, Stefano; Lamberti, Paolo; Iliceto, Giovanni; Diroma, Cosimo; Armenise, Elio; Defazio, Giovanni; Lamberti, Simona V.; Fraddosio, Angela; de Mari, Michele; Livrea, Paolo

Book ID: 120379985
Publisher: Walter de Gruyter GmbH & Co. KG
Year: 2005
Tongue: English
Weight: 73 KB
Volume: 43
Category: Article
ISSN: 1434-6621
DOI: 10.1515/CCLM.2005.193

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tolcapone decreases plasma levels of S-a

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients

✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 97 KB

Longevity in Parkinson's disease treated

Longevity in Parkinson's disease treated with L-DOPA

✍ Birkmayer, W.; Ambrozi, L.; Neumayer, E.; Riederer, P. 📂 Article 📅 1974 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Impaired transmethylation potential in P

Impaired transmethylation potential in Parkinson's disease patients treated with l-Dopa

✍ Maria Luigia De Bonis; Alessandro Tessitore; Maria Teresa Pellecchia; Katia Long 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 276 KB

2.275 L-Dopa plasma levels variability i

2.275 L-Dopa plasma levels variability in Parkinson's disease

✍ G. Albani; S. Cattaldo; A. Mauro 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 128 KB

L-Dopa therapy increases homocysteine co

L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson’s disease

✍ Chiaki Isobe; Takashi Abe; Yasuo Terayama 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Cognitive dysfunctions and pathological

Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease

✍ Gabriella Santangelo; Carmine Vitale; Luigi Trojano; Francesca Verde; Dario Gros 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract The purpose of this study was to investigate the neuropsychological correlates of pathological gambling (PG) in Parkinson's disease (PD). Fifteen patients with PD affected by PG (identified based on DSM‐IV criteria; PD+PG) without clinically evident dementia were compared with 15 nondem